Early Phase 1 COPD Trial, Recruiting NCT07355868 Sponsor: Regend Therapeutics Condition: COPD
Back to Copd

Early Phase 1 COPD Trial, Recruiting

NCT07355868
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 40 and 80 years old (both ages included), and any gender may apply
  • You have been diagnosed with COPD (a lung condition) according to the 2025 international COPD guidelines
  • During a screening walking test, you are able to walk at least 150 metres but less than 600 metres in six minutes
  • You are willing to sign a consent form, take part in study-related visits and tests, and keep track of any changes in how you feel

Who may not be able to join:

  • You are a woman who is pregnant, breastfeeding, or planning to become pregnant within one year of using the study treatment, or you are a man whose partner is planning to become pregnant
  • The study doctor believes your life expectancy is less than one year at the time of screening
  • You have a current or past history of cancer, with some exceptions for certain cancers that have been in remission for more than five years and are considered less aggressive by the doctor (confirm with trial site)
  • You had pneumonia (bacterial, fungal, or viral) within the four weeks before screening
  • You have had more than four moderate or severe COPD flare-ups requiring hospitalisation in the year before screening
  • You have had a confirmed or suspected COVID-19 infection within the four weeks before screening
  • You have ever needed a breathing machine (invasive or non-invasive ventilation) at any point
  • You currently have active tuberculosis, poorly controlled asthma, acute blood clot in the lungs, or severely high blood pressure in the lungs (above 70 mmHg on heart scan)
  • You have had a serious non-lung illness in the six months before screening, such as a heart attack, severe heart failure, stroke, severe liver or kidney disease, or a serious diabetes emergency
  • You have severe anaemia, or poorly controlled low white blood cell or platelet counts at the time of screening
  • You have a history of suicidal thoughts, a psychiatric condition, or epilepsy
  • You have severe malnutrition at the time of screening
  • Your heart tracing (ECG) shows a serious abnormal heart rhythm, such as atrial fibrillation, atrial flutter, or certain other irregular heartbeats
  • You have taken part in another clinical trial or received a biological medicine treatment within the four weeks before screening
  • You are a member of the research team, an employee of the study centre, or a close family member of any of those people
  • The study doctor considers you unsuitable for any other reason that could increase your risk or affect the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 086-0579-89935016

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Regend Therapeutics
Registry
ClinicalTrials.gov
Start date
19 March 2026
Est. completion
15 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence and severity of drug-related adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov